Pexmetinib is under clinical development by Pfizer and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Pexmetinib’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pexmetinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Pexmetinib (ARRY-614) is under development for the treatment of melanoma, renal cell carcinoma and advanced solid tumors. The drug candidate is administered orally. It acts by targets p38alpha MAP kinase(MAPK14) and Tie2 kinases. It was also under development for myelodysplastic syndrome (MDS).
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
Quick View Pexmetinib LOA Data
|Highest Development Stage|